Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence, awareness, treatment, and control rates of hypertension in the general population of Australia: a systematic review and meta-analysis.

Journal of hypertension·2024

Same author

Impact of Age, Frailty, and Dementia on Prescribing for Type 2 Diabetes at Hospital Discharge 2012-2016.

The Journal of frailty & aging·2021

Same author

Improving systems of care during and after a pregnancy complicated by hyperglycaemia: A protocol for a complex health systems intervention.

BMC health services research·2020

Same author

Diabetes care in remote Australia: the antenatal, postpartum and inter-pregnancy period.

BMC pregnancy and childbirth·2019

Same author

Birth outcomes in women with gestational diabetes managed by lifestyle modification alone: The PANDORA study.

Diabetes research and clinical practice·2019

Same author

Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?

Diabetic medicine : a journal of the British Diabetic Association·2019

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

Anti-platelets in diabetes management.

N M Grantham¹, D J Magliano, G Tai

¹Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. Narelle.grantham@bakeridi.edu.au

Internal Medicine Journal

|July 20, 2010

Summary

Diabetic patients with cardiovascular disease (CVD) frequently use anti-platelet therapy. For those without CVD but with risk factors, low anti-platelet use is not explained by contraindications, indicating a potential gap in preventative care.

More Related Videos

Purification of Platelets from Mouse Blood

Purification of Platelets from Mouse Blood

Published on: May 7, 2019

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 10, 2026

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

Purification of Platelets from Mouse Blood

Purification of Platelets from Mouse Blood

Published on: May 7, 2019

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

Cardiology
Diabetology
Pharmacology

Background:

Diabetes mellitus is a significant risk factor for cardiovascular disease (CVD).
Anti-platelet therapy is crucial for preventing thrombotic events in patients with or at high risk for CVD.
Optimizing anti-platelet use in diabetic populations is essential for cardiovascular risk reduction.

Purpose of the Study:

To determine the prevalence of anti-platelet therapy use in diabetic patients.
To assess the role of contraindications in limiting anti-platelet therapy prescription in this cohort.
To evaluate anti-platelet prescribing patterns in relation to cardiovascular disease history and risk factors.

Main Methods:

Retrospective analysis of 726 diabetic patients attending a private clinic.
Data collection on anti-platelet medication use, history of cardiovascular disease (CVD), and presence of CVD risk factors.
Assessment of contraindications to anti-platelet therapy.

Main Results:

87.1% of diabetic patients with a history of CVD were on anti-platelet therapy.
Among diabetic patients without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy.
Only 7.1% of those not on anti-platelet therapy had a documented contraindication, suggesting underutilization.

Conclusions:

High utilization of anti-platelet therapy is feasible in diabetic patients with established CVD.
Contraindications do not adequately explain the low use of anti-platelet therapy in diabetic patients without prior CVD but with risk factors.
There may be opportunities to improve secondary prevention strategies through increased anti-platelet use in high-risk diabetic patients.